About US
Contact us
-
Roche, Pfizer win FDA nods for targeted cancer drugsRoche ($RHHBY) and Genentech won a landmark approval for the cancer drug vismodegib today. After gaining significant efficacy data from a Phase II study on basal cell carcinoma, the drug giant not onl2012/1/31
-
Lipitor brand loses ground as generics take holdPfizer ($PFE) faces another stumbling block on its Lipitor obstacle course. As The Wall Street Journal reports, Express Scripts ($ESRX) is moving the cholesterol drug to a less-favorable spot on i2012/1/31
-
FDA weighs crackdown on 'distracting images' in DTC adsIn every pharmaceutical television commercial there's the bit at the end while a voiceover intones a litany of potential side effects anddrug warnings likely to startle anyone thinking of taking it.2012/1/31
-
Ax hovers over 3,000 more AstraZeneca jobs, U.K. papers sayThe 2012 layoffs toll may continue to mount. British newspapers are reporting that AstraZeneca's ($AZN) cost-squeezing program could grow by another 3,000 or so job cuts. The company is said to be2012/1/30
-
Jimenez counts on 7 drugs to take Novartis past DiovanMaybe it's the rarefied Davos air or the long-range mountain views, but Novartis ($NVS) CEO Joe Jimenez is feeling optimistic about the post-Diovan future. After the Swiss drugmaker loses patent pro2012/1/30
-
Sanofi, Novartis favor diagnostics partnerships over M&AThe initial speculation--or was it a wish?--that a Sanofi ($SNY) or Novartis ($NVS)might mount a counterbid to Roche's hostile $5.7 billion offer for Illumina was chilled rather effectively by a sto2012/1/30
-
Europe makes Sanofi chief thankful for emerging marketsAlthough Sanofi ($SNY) CEO Christopher Viehbacher (photo)sees a glimmer of light at the end of the long Eurozone tunnel, he's still glad the French drugmaker doesn't depend on Europe as much as it u2012/1/29
-
Murdoch bows out of GSK board to focus on workNews Corp's James Murdoch has enough on his plate these days, what with moving to the U.S. and taking over as COO, not to mention answering pointed questions about that phone-hacking scandal. No tim2012/1/29
-
Foreign pharma deals snag on new Indian rulesPharma companies are seeing the fallout from new M&A rules adopted by the Indian government. Late last year,Indian officials introduced a new deal-review process that has replaced the automati2012/1/21
-
Pharma's earnings laggards are dividend starsAs we move into earnings season, Reuters has crunched the numbers on your favorite Big Pharma companies and put the results into a handy-dandy bar chart that ranks them by various measures: P/E rati2012/1/21